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Abstract
Introduction: Since the beginning of the HIV epidemic in resource-rich countries, Pneumocystis jirovecii pneumonia (PjP) is one
of the most frequent opportunistic AIDS-defining infections. The Collaboration of Observational HIV Epidemiological Research
Europe (COHERE) has shown that primary Pneumocystis jirovecii Pneumonia (PjP) prophylaxis can be safely withdrawn in
patients with CD4 counts of 100 to 200 cells/µL if plasma HIV-RNA is suppressed on combination antiretroviral therapy.
Whether this holds true for secondary prophylaxis is not known, and this has proved difficult to determine due to the much
lower population at risk.
Methods: We estimated the incidence of secondary PjP by including patient data collected from 1998 to 2015 from the
COHERE cohort collaboration according to time-updated CD4 counts, HIV-RNA and use of PjP prophylaxis in persons
>16 years of age. We fitted a Poisson generalized additive model in which the smoothed effect of CD4 was modelled by a
restricted cubic spline, and HIV-RNA was stratified as low (<400), medium (400 to 10,000) or high (>10,000copies/mL).
Results: There were 373 recurrences of PjP during 74,295 person-years (py) in 10,476 patients. The PjP incidence in the dif-
ferent plasma HIV-RNA strata differed significantly and was lowest in the low stratum. For patients off prophylaxis with CD4
counts between 100 and 200 cells/µL and HIV-RNA below 400 copies/mL, the incidence of recurrent PjP was 3.9 (95% CI:
2.0 to 5.8) per 1000 py, not significantly different from patients on prophylaxis in the same stratum (1.9, 95% CI: 0.1 to 3.7).
Conclusions: HIV viraemia importantly affects the risk of recurrent PjP. In virologically suppressed patients on ART with CD4
counts of 100 to 200/µL, the incidence of PjP off prophylaxis is below 10/1000 py. Secondary PjP prophylaxis may be safely
withheld in such patients. While European guidelines recommend discontinuing secondary PjP prophylaxis only if CD4 counts
rise above 200 cells/mL, the latest US Guidelines consider secondary prophylaxis discontinuation even in patients with a CD4
count above 100 cells/µL and suppressed viral load. Our results strengthen and support this US recommendation.
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1 | INTRODUCTION
Since the beginning of the HIV epidemic in resource-rich
countries, Pneumocystis jirovecii pneumonia (PjP) is one of the
most frequent opportunistic AIDS-defining infections [1]. PjP
occurs predominantly in people living with HIV (PLWH) with
marked immunodeficiency with CD4 positive lymphocytes in
peripheral blood (CD4 count) of less than 200 cells/µL, or less
than 14 % of total lymphocytes [2]. In the era before potent
antiretroviral therapy (ART) this led to the recommendation of
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providing life-long primary chemoprophylaxis against PjP in all
PLWH with a CD4 count below this threshold. While PjP inci-
dence decreased substantially in the era of ART it still occurs
in patients presenting late during their HIV infection, in those
lost to care, those non-adherent or failing ART [3,4]. The risk
of recurrence of PjP after successful treatment of a first epi-
sode was shown to be particularly high [5,6]. This may in part
be due to genetic susceptibility for PjP [7]. Therefore, sec-
ondary prophylaxis or maintenance therapy was recommended
for all patients having experienced PjP [8].
With the advent of potent ART, several studies have shown
that primary and secondary PjP prophylaxis can be safely dis-
continued once the CD4 count rises to above 200 cells/µL [9-
14].
Within the large Collaboration of Observational HIV Epi-
demiological Research in Europe (COHERE), we have previ-
ously shown that HIV viraemia as measured by plasma HIV-
RNA is an additional important risk factor for PjP, independent
of the CD4 count. Primary PjP prophylaxis may be safely with-
held in patients on successful ART, with CD4 counts between
100 and 200 cells/µL [15]. In patients in this CD4 count stra-
tum, with plasma HIV RNA below 400 copies/ML and off pro-
phylaxis the incidence of primary PjP was 12 (95% CI 2 to
45) events per 1000 person-years (py). A more recent analy-
sis pointed towards safety of discontinuing prophylaxis even in
all patients that achieve undectable plasma HIV-RNA levels
[16]. Similar findings were reported by smaller cohorts [17-
19], a randomized trial [20] and in two systematic reviews
[21,22]. While the combined results of discontinuation of pri-
mary prophylaxis in the patients of interest indicated an inci-
dence with a 95% confidence interval upper boundary below
10/1000 py, the data on discontinuation of secondary prophy-
laxis remained inconclusive [19,20,22]. Nevertheless, in recent
years many physicians stopped prescribing PjP prophylaxis in
patients on successful ART, even with low CD4 counts [23].
We evaluated the risk of secondary PjP in patients on and
off prophylaxis at different levels of CD4 count and plasma
HIV-RNA based on a large database with long follow-up.
2 | METHODS
2.1 | Setting
COHERE in EuroCoord was a collaborative group of adult,
pediatric, and mother/child HIV cohorts across Europe. The
collaboration allows comparisons across age categories and
provides a mechanism to rapidly compile datasets to address
novel research questions that cannot be studied adequately in
individual cohorts (www.eurocoord.net, www.cohere.org) [24].
Data were extracted from the 2015 merger of COHERE that
included 23 European cohorts, with information on patient
characteristics (age, sex and transmission category), use of
ART (type of regimen and dates of start and discontinuation),
CD4 cell counts and plasma HIV-RNA over time and their
dates, AIDS-defining conditions and indicator variables for
drop-out or death.
2.2 | Analysis
The results are reported as median and interquartile ranges
for the quantitative variables, whereas those for qualitative
variables are expressed as absolute frequency along with the
associated percentage. The Kruskal–Wallis test was used for
continuous and Fisher’s exact test for categorical variables.
We calculated the incidence rate (events per 1000py) strat-
ified by current use of PjP-prophylaxis and by plasma HIV-
RNA levels (<400, 400 to 10,000 copies/mL and
>10,000 copies/mL). Poisson regression with a log link func-
tion was used to analyze associations between the incidence
of PjP diagnosis, dependent on the use of secondary prophy-
laxis. Follow-up started at the first visit at which the inclusion
criteria were met (16 years of age or over, began follow-up in
their cohort after 1998, and a previous PjP diagnosis). As
potential risk factors, we included gender (reference male),
age, probable mode of HIV transmission (with categories men
having sex with men (MSM) (reference), intravenous drug use
(IDU), heterosexual and “other”), current HIV RNA level, cur-
rent CD4 count and the contributing cohort. We fitted
restricted cubic splines to model the smoothed effect of
changing CD4 count over time using general additive Poisson
models, calculated with sandwich-type standard errors to
adjust for patients contributing multiple periods of follow-up
time. These spline models enable the visualization of the inci-
dence trajectory for continuous CD4 counts in a given viral
load stratum. We varied the number of knots used for the
splines to investigate the goodness of fit and to avoid
overfitting.
The level of missingness for baseline and time-varying vari-
ables was considered negligible (<10%), and therefore we did
not resort to using formal missing data methods in the analy-
sis. Last observation carried forward was used to impute miss-
ing post-baseline CD4 and RNA measurements.
All analyses were carried out with R version 3.2.4, using the
function “gam” in package “mgcv” to fit the general additive
models [25,26]. Throughout we considered a level of 0.05 as
statistically significant.
2.3 | Ethical approval
Ethical approval was applied for and granted for the research
from the appropriate body in the host country of the cohort
contributing the data to COHERE.
2.4 | Patient consent
Patient consent was obtained by each of the cohorts as
defined locally as a pre-requisite for sharing information with
the COHERE collaboration.
3 | RESULTS
There were 10,476 patients with PjP and a follow-up time of
74,295 py at risk for secondary PjP. The overall incidence was
5.0 [4.5, 5.6] per 1000 py for 373 secondary PjP events
occurring in the period 1998 to 2015. Patient characteristics
for the total population and for those who did or did not
develop secondary PjP are shown in Table 1. Those who
developed secondary PjP were more likely to be female and
infected by intravenous drug use. They were also younger and
had lower CD4 counts and higher plasma HIV RNA at
baseline.
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Figure 1 and Table 2 depict the incidence in patients at risk
of secondary PjP. The incidence of recurrent PjP in the low
HIV-RNA stratum with CD4 counts 100 to 200 cells/µL for
patients off secondary prophylaxis was estimated to be 3.9
(95% CI: 2.0 to 5.8) events per 1000 py (Figure 1a), as com-
pared to 1.9 (95% CI 0.1 to 3.7; p = 0.1) on prophylaxis. In
patients with suppressed viral load, we could exclude an inci-
dence of more than 10/1000py for those with current CD4
counts of at least 95 cells/ µL at a 95% confidence level.
Even in patients off prophylaxis in the CD4 count stratum
below 100 cells/µL with suppressed viral load, the PjP inci-
dence was low at 8.9/1000 py (95% CI 3.3 to 12.9). Fig-
ure 1b presents the estimates from the fitted Poisson model
for a reference patient (35-year old, male MSM) with a cubic
spline smoother for the CD4 count, stratified by level of viral
suppression (low, medium and high). According to this model,
the upper boundary of the 95% confidence interval of PjP
incidence increased to more than 20/1000 years in patients
with very low CD4 counts (Figure 1b, left panel). As depicted
in Figure 1b left panel, we found an incidence of <10/1000 py
in patients with CD4 counts higher than 95 cells/µL at a 95%
confidence level. There was a marginally significant higher risk
for patients with transmission risk IDU compared to MSM as
reference (RR 1.3, 95% CI 1.0 to 1.80 p = 0.05). The supple-
mentary Figure presents the estimates from the fitted Poisson
model for a 35-year old, male IDU reference patient.
Viral replication was strongly associated with higher PjP
incidence at every current CD4 count stratum (Table 2 and
Figure 1) both for patients on and off prophylaxis. In fact, in
patients with plasma HIV RNA above 10,000 c/mL we could
not exclude an incidence of less than 10/1000 py for patients
with current CD4 counts of more than 200 cells/lL in
patients off or on prophylaxis (Figure 1b). The supplementary
Table shows the estimates of incidence rate ratios from the
fitted model for several risk factors.
4 | DISCUSSION
HIV viraemia is an independent major risk factor for sec-
ondary PjP, as we have previously demonstrated to be the
case for primary PjP [15]. For patients on ART with sup-
pressed viral load, the risk for secondary PjP is below 10/
1000 py once their CD4 count has risen to above 95 cells/
µL.
However, the risk for secondary PjP remains above 10/
1000 py, even with CD4 counts of >200 cells/µL, in case of
replicating HIV with a plasma HIV-RNA level above
10,000 copies/mL.
Secondary PjP prophylaxis can therefore be safely discontin-
ued in asymptomatic patients on ART with plasma viral loads
of <400 copies/mL, a CD4 count above 100 cells/µL, and no
other risk factors for PjP, such as additional immunosuppres-
sion or chronic lung disease. This would allow stopping or
withholding secondary prophylaxis in most Western European
patients with current CD4 counts between 100 and
200 cells/µL since viral suppression is achieved in more than
80% in patients on ART [27].
HIV replication has been shown to be an important, and
CD4 count an independent, factor interfering with immuno-
competence. It has also been associated with a higher risk of
tuberculosis [28], and with a lower response to vaccination
against yellow fever [29], influenza [30] and hepatitis B [31].
Taking an upper 95% confidence limit for the incidence of
PjP to be less than 10/1000 py as a threshold to safely with-
holding prophylaxis is somewhat arbitrary. However, in many
of the pivotal studies defining the safety of discontinuation of
PjP prophylaxis, the upper 95% confidence level of incidence
was in this range, or even slightly higher [9-15]. Showing the
smoothed effect of current CD4 count on incidence of PjP by
fitting the spline models (Figure 1b) allows the treating physi-
cians to define the safety margin themselves, based on our
Table 1. Characteristics of patients at baseline for those with and without a secondary PjP diagnosis during follow-up
Overall No secondary PjP diagnosis Secondary PjP diagnosis p-value
Number of patients 10476 10103 373 –
Female (%) 2082 (19.9%) 1987 (19.7%) 95 (25.5%) <0.001
Age at baseline (median [IQR]) 40 [35, 47] 40 [35, 48] 38 [34, 44] <0.001
HIV transmission mode (%)
MSM 4144 (39.6) 4020 (39.8%) 124 (33.2%) <0.001
Heterosexual 3544 (33.8) 3429 (33.9%) 115 (30.8%)
IDU 1390 (13.3) 1309 (13.0%) 81 (21.7%)
Other, unknown 394 (3.4) 373 (3.7) 21 (5.6%)
Missing 1004 (9.6) 972 (9.6%) 32 (8.6%)
CD4 count/µL (median [IQR])
Baseline 80 [24, 220] 80 [25, 221] 64 [22, 190] 0.07
At final follow-up visit – 415 [220, 628] 100 [29, 270] <0.001
Plasma HIV-RNA/mL (median [IQR])
Baseline 71882 [500, 308000] 70000 [500, 306000] 101000 [11500, 351064] <0.001
At final follow-up visit – 49 [22, 79] 24400 [155, 210000] <0.001
Follow-up time in years per patient (median [IQR]) – 6.5 [2.7, 11.5] 1.9 [0.6, 3.9] <0.001
Percentage of follow-up on ART (median [IQR]) – 96% [65%, 100%] 99% [64%, 100%] 0.1
ART, antiretroviral therapy; IDU, intravenous drug use; IQR, interquartile range; MSM, men who have sex with men; PjP, pneumocystis jirovecii
pneumonia.
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Figure 1. Incidence of secondary Pneumocystis Pneumonia (PjP). (a) Stratified by CD4 count (cells/µL) and plasma HIV-RNA (copies/mL) levels
for those on or off PjP prophylaxis; point estimates indicated by circles with 95% confidence intervals as vertical error bars. (b) Stratified plasma
HIV-RNA levels from those off (left panel) and on (right panel) PjP prophylaxis. Plasma HIV-RNA levels: High >10,000, Medium 400-10,000, Low
<400 copies/mL. From the fitted Poisson general additive model for a 35 year old, male, MSM with 95% confidence intervals shown shaded in
the respective colour. HIV, human immunodeficiency viruses; HIV-RNA, human immunodeficiency viruses (HIV) Ribonucleic acid; MSM, men who
have sex with men; PjP, Pneumocystis jirovecii pneumonia; Py, person years; Py, person years; RNA, Ribonucleic acid; VL, Viral load
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large observational database. The results of the models also
show that within the stratum of CD4 counts of 100 to
200 cells/µL the incidence is not stable but is double at the
lower end of this stratum compared to the higher end. There-
fore, results relying on strata must be interpreted with cau-
tion.
Not being able to exclude an incidence of secondary PjP of
less than 10/1000 py in patients with CD4 counts above
200 cells/µL in patients on virologically failing ART was
intriguing, because CD4 counts in this range are generally
considered protective for secondary PjP. This underlines the
major influence of HIV replication on immune competence.
Thus, our results even point towards a reconsideration of sec-
ondary prophylaxis against PjP in patients with established
virological failure due to non-adherence or non-suppressive
ART, even if they have a CD4 count above 200 cells/µL.
Furthermore, counterintuitively incidence seems to increase
for those with “high” HIV-RNA and CD4 >200 cells/lL when
on prophylaxis (Figure 1b right-hand side, red curve). While
the apparent upwards trend could be due to overfitting of the
spline curve, one has to consider that the follow-up in this
population is less than 5% of the follow-up in PLWH with
CD4 counts >200, and we did not find a statistically signifi-
cant difference in incidence for these people relative to pro-
phylaxis. Nevertheless, highly replicating HIV would imply non-
adherence to treatment or non-suppressive ART. If non-
adherence to ART is the reason for replicating HIV, there may
also have been non-adherence to prophylaxis, which could
explain an increased incidence for those on prophylaxis.
Current European and US Guidelines have been adapted
recently to recommend discontinuation of primary PjP prophy-
laxis in patients with sustained viral suppression and CD4
counts above 100 cells/µL [32,33]. While European guidelines
recommend discontinuing secondary PjP prophylaxis only if
CD4 counts rise above 200 cells/mL, the latest US Guidelines
consider secondary prophylaxis discontinuation even in
patients with a CD4 count above 100 cells/µL and suppressed
viral load. Our results importantly strengthen and support this
US recommendation.
Our study has the general limitations of observational analy-
ses of multicohort collaborations. The analysis included data
up to 2015, and therefore excludes more recent clinical prac-
tice and treatments. We did not verify single patient data for
PjP events. However, the endpoint of PjP is clearly defined in
all the collaborating cohorts. We used a plasma HIV-RNA
threshold of 400 copies/mL as a surrogate for viral suppres-
sion, whereas a viral load of less than 50 copies/mL more ade-
quately defines viral suppression. By using the higher
threshold our data about the safety of secondary prophylaxis
discontinuation is consequently more conservative, and in
practice, also allows discontinuing prophylaxis in patients with
viral blips between 50 and 400 copies/mL.
In our model, patients were not required to have a plasma
viral load <400 copies/mL for a certain time to be included in
the low viraemia stratum. In clinical practice, it might however
be advisable to discontinue prophylaxis once undetectable vir-
aemia has been confirmed by more than a single measure-
ment.
Table 2. Incidence of secondary Pneumocystis Pneumonia (PjP) stratified by CD4 count (cells/µL) and plasma HIV-RNA (copies/mL)
and being on or off prophylaxis






person years) Incidence [95% CI]
<100 <400 No 11 1353.9 8.1 [3.3, 12.9]
<100 <400 Yes 7 887.0 7.9 [2.0, 13.7]
<100 400 to 10,000 No 10 545.6 18.3 [7.0, 29.7]
<100 400 to 10,000 Yes 5 369.2 13.5 [1.7, 25.4]
<100 >10,000 No 114 1920.4 59.3 [48.5, 70.3]
<100 >10,000 Yes 40 1098.5 36.4 [26.0, 49.6]
101 to 200 <400 No 16 4085.6 3.9 [2.0, 5.8]
101 to 200 <400 Yes 4 2096.7 1.9 [0.1, 3.7]
101 to 200 400 to 10,000 No 8 852.9 9.4 [2.9, 15.8]
101 to 200 400 to 10,000 Yes 3 499.4 6.0 [0.1, 12.8]
101 to 200 >10,000 No 18 814.0 22.1 [11.9, 32.3]
101 to 200 >10,000 Yes 7 448.3 15.6 [4.1, 27.2]
>200 <400 No 73 48776.8 1.5 [1.2, 1.8]
>200 <400 Yes 10 3728.5 2.7 [1.0, 4.3]
>200 400 to 10,000 No 14 3707.6 3.8 [1.8, 5.8]
>200 400 to 10,000 Yes 4 810.5 4.9 [0.1, 10.0]
>200 >10,000 No 20 1936.6 10.3 [5.8, 14.9]
>200 >10,000 Yes 9 363.9 24.7 [8.6, 40.9]
CI, confidence interval; HIV, human im.7munodeficiency viruses, PjP, pneumocystis pneumonia, RNA, ribonucleic acid.
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Lower age and IDU as HIV-transmission risk were both
associated with a somewhat higher risk of secondary PjP,
which, as pointed out in other studies, might be an indication
of lower ART adherence. In addition, co-infections such as
active hepatitis C could further compromise immune-
competence in IDUs.
Our recommendation may not apply to all geographical set-
tings. Co-trimoxazole prophylaxis has been shown to be asso-
ciated with lower morbidity and mortality in patients with
higher CD4 cell counts in Sub-Saharan Africa, mainly due to
its effectiveness in preventing infections other than PjP
[34,35]. Furthermore, our findings result from averaging data
from many countries, and therefore individual settings may
require a slightly more conservative approach.
5 | CONCLUSIONS
In conclusion, in the absence of other risk factors, secondary
PjP prophylaxis can be safely discontinued, or withheld, in
patients who have both a CD4 count above 100 cells/µL and
a suppressed viral load on ART. Conversely, it may be war-
ranted to prescribe prophylaxis for viraemic patients with a
viral load greater than 10,000 copies/mL, even those having a
CD4 count above 200 cells/µL.
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Table S1. Estimates of incidence rate ratios (IRR) for secondary
Pneumocystis jirovecii pneumonia (PjP) from the fitted general
additive model with a cubic spline smoother for CD4 count. In
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addition, there was a highly significant association of PjP with
lower CD4 counts (p < 0.001). CI, Confidence interval; IDU,
intravenous drug use; MSM, men who have sex with men
Figure S1. Incidence of secondary Pneumocystis Pneumonia
(PjP) stratified plasma HIV-RNA levels from those off (left
panel) and on (right panel) PjP prophylaxis. Plasma HIV-RNA
levels: High >10,000, Medium 400-10,000, Low <400 copies/
mL. From the fitted Poisson general additive model for a 35-
year-old male IDU patient with 95% confidence intervals
shown shaded in the respective colour.
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